Changes in Bone Mineral Density After 96 Weeks of Treatment With Atazanavir/Ritonavir or Lopinavir/Ritonavir Plus Tenofovir DF/Emtricitabine in Treatment-Naive Patients With HIV-1 Infection
| Autor: | St John McGrath, Awny Farajallah, Graeme J. Moyle, Helene Hardy, Douglas J. Ward, Stephen Kaplita |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Anti-HIV Agents Pyridines Atazanavir Sulfate Lopinavir/ritonavir HIV Infections Emtricitabine Gastroenterology Lopinavir Absorptiometry Photon Bone Density immune system diseases Internal medicine Humans Medicine Pharmacology (medical) Bone mineral Ritonavir business.industry virus diseases Confidence interval Atazanavir Infectious Diseases Multivariate Analysis Body Composition HIV-1 Tenofovir DF business Oligopeptides medicine.drug |
| Zdroj: | JAIDS Journal of Acquired Immune Deficiency Syndromes. 68:40-45 |
| ISSN: | 1525-4135 |
| Popis: | Antiretroviral therapy initiation is associated with declines in bone mineral density (BMD), which seem greatest with tenofovir disoproxil fumarate (DF)-containing regimens. Data comparing protease inhibitors are limited. This CASTLE substudy compared paired baseline with week 96 BMD in patients initiating tenofovir DF/emtricitabine plus atazanavir/ritonavir (n = 106) vs lopinavir/ritonavir (n = 70). In both groups, week 96 BMD declined significantly in arm, leg, trunk, and total body regions. Atazanavir/ritonavir was associated with smaller 96-week trunk and total body BMD declines compared with lopinavir/ritonavir [multivariate-adjusted least squares mean difference +2.00% (95% confidence interval: 0.52 to 3.45; P = 0.008) and +1.24% (95% confidence interval: 0.13 to 2.35; P = 0.029), respectively]. In addition, low baseline CD4 cell count ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|